Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,”
“us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical
company that is pioneering advanced treatment applications for
cancers throughout the body, today announced third quarter
financial results for the period ended September 30, 2024.
“Since our team initiated dosing of U.S.
patients in two clinical programs in 2023, important learnings on
each of these two clinical-stage constructs and the applicability
of our proprietary radiopharmaceutical platform in a variety of
clinical settings have informed our strategy to bring innovative
precision medicines to patients based on alpha-emitting isotopes
and targeting moiety optimization,” said Thijs Spoor, Perspective’s
CEO. “At the time same, we continue to invest in developing
proprietary compounds and building out a network of regional
manufacturing sites to service treatment centers and patients,
which currently consists of two active sites as well as three
buildings being modified in anticipation of delivery of equipment
already on order. We look forward to continued progress in the
coming months and in 2025.”
Program
HighlightsVMT-α-NET
Company-sponsored Phase 1/2a trial of
[212Pb]VMT-α-NETWe are conducting a multi-center
open-label dose escalation, dose expansion study
(clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in
patients with unresectable or metastatic somatostatin receptor type
2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not
received prior radiopharmaceutical therapies (RPT). We received
Fast Track Designation for this program from the U.S. Food and Drug
Administration (FDA) based on preclinical data for SSTR2-positive
NETs regardless of prior treatment response.
As stated in our 2Q 2024 quarterly update in
August 2024, the observation period was completed for dose limiting
toxicity (DLT) in seven patients enrolled in Cohort 2 during the
second quarter of 2024. Subsequently, the Safety Monitoring
Committee (SMC) determined that safety observations during the DLT
period supported proceeding with dose escalation to Cohort 3 and
increasing the number of patients dosed at 5 mCi (up to 40 more
patients). Based on FDA interactions prior to the initiation of
patient dosing in this study, the decision to open Cohort 3 will
follow consultation and alignment with the agency.
During the quarter, data informing the SMC’s
recommendation were submitted to and accepted for presentation at
the 2024 North American Neuroendocrine Tumor Society (NANETS)
Multidisciplinary NET Medical Symposium taking place November
21-23, 2024 in Chicago. We will host an investor call at the start
of the conference; details on the call will be available prior to
the conference.
Investigator-initiated clinical research
of [212Pb]VMT-α-NETWe are collaborating with a number of
thought leaders to further elucidate the clinical profile of
[212Pb]VMT-α-NET through investigator-initiated studies in the U.S.
as well as overseas.
Investigator Led Study in
IndiaThis is an exploratory first-in-human use of
[212Pb]VMT-α-NET in adult patients with histologically confirmed
metastatic NETs and medullary thyroid carcinomas in an
investigator-led research study. A total of 13 patients were
enrolled: 10 patients with gastroenteropancreatic-NETs (GEP-NETs),
one patient with breast NETs, and two patients with medullary
thyroid carcinomas.
The most recent scientific conference
presentation by the investigator was during the 37th Annual
Congress of the European Association of Nuclear Medicine (EANM)
meeting in October 2024. The investigator reported updated safety
and anti-tumor activity of [212Pb]VMT-α-NET administered at 67
µCi/kg (2.5 MBq/kg) every 8 weeks for up to 6 doses in 10 patients
with GEP-NETs as of the data cut-off date of September 15, 2024.
All patients received prior treatments, seven of whom received
prior RPT treatment.
The investigator concluded that the toxicity
profile suggests the potential for dose escalation to achieve
optimal treatment responses. Confirmed tumor response per RECIST
1.1 was reported to be observed in six of the 10 patients, while
unconfirmed responses were observed in two additional patients who
eventually had progressive disease and died. The investigator also
reported higher absorbed doses in the tumors compared to select
other tissues.
VMT01We designed VMT01 to
target and deliver 212Pb to tumor sites expressing melanocortin 1
receptor (MC1R), a protein that can be overexpressed in metastatic
melanoma tumors. We are conducting a multi-center, open-label dose
escalation, dose expansion study (clinicaltrials.gov identifier
NCT05655312) in previously treated patients with histologically
confirmed melanoma and MC1R-positive imaging scans.
- In July 2024, we submitted a
protocol amendment to explore the combination of the checkpoint
inhibitor nivolumab with [212Pb]VMT01 in patients with
histologically confirmed melanoma and positive MC1R imaging scans
in our ongoing Phase 1/2a study of [212Pb]VMT01. The first
combination cohort is now open for enrollment. The supply of
nivolumab was secured in March 2024, when we entered into a
clinical trial collaboration agreement with Bristol Myers Squibb
(NYSE: BMY).
- As of August 9, 2024, we initiated
dosing of a total of 10 patients in Cohort 1 and in Cohort 2 of the
Phase 1/2a clinical study of [212Pb]VMT01 in patients with
progressive MC1R-positive metastatic melanoma. A total of seven
patients received activities of 5mCi of [212Pb]VMT01 in Cohort
2.
- On September 5, 2024, we announced
the FDA granted Fast Track Designation for the development of
[212Pb]VMT01 for the diagnosis and treatment of patients with
unresectable or metastatic melanoma and who have demonstrated MC1R
tumor expression.
On October 11, 2024, we announced initial
results from the first two dosing cohorts. Three patients were
enrolled in Cohort 1 (who received 3 mCi of [212Pb]VMT01), while
seven patients were enrolled in Cohort 2 (who received 5 mCi of
[212Pb]VMT01). Patients in each cohort received a median of five
prior lines of systematic therapy, including a median of three
prior lines of immunotherapy.
- Safety findings:
No dose-limiting toxicities were observed among any patients, and
no adverse events led to treatment discontinuation. Treatment
emergent adverse events (TEAEs) were mostly Grades 1 and 2. None of
the four cases of grade 3 TEAEs were deemed to be treatment
related. There were no grade 4 or 5 TEAEs. No renal toxicities had
been reported as of October 11, 2024 (there were no clinically
significant changes in blood urea nitrogen or serum creatinine) in
spite of dosimetry estimated renal radiation that approached the
higher end of conventional dosing.
- Efficacy findings:
All patients in Cohort 1 completed three treatments, with one
patient experiencing an unconfirmed RECIST version 1.1 objective
response after completion of treatment, and two patients
experiencing stable disease at 9 and 11 months from the start of
treatment, respectively. In Cohort 2, patients progressed after
either the first cycle (three patients) or the second cycle (four
patients). These findings are consistent with published and ongoing
preclinical studies showing immunostimulatory effects at lower
radiation doses.
The SMC reviewed these findings and recommended
exploring a lower dose level of 1.5 mCi per dose, both as a single
agent and in combination with the anti-PD-1 antibody, nivolumab.
The SMC’s recommendation would allow for the monotherapy and
combination cohorts to proceed concurrently. An amendment to
further explore lower dose levels for monotherapy is planned. The
combination cohort at 1.5 mCi per dose with nivolumab is active and
now open for enrollment.
Status of pre-IND assetsWe have
multiple assets in pre-IND development and expect to advance
several pre-IND assets into the clinic in the next 9-18 months.
- PSV359 is an
internally discovered molecule that targets fibroblast activation
protein-α, or FAP-α, associated with a variety of solid tumors.
Preclinical imaging and therapy as well as human imaging results
suggest our proprietary targeting ligand has improved levels of
target engagement and uptake in tumors and reduced retention in
healthy tissues that may result in a desirable therapeutic index.In
October 2024, we announced first-in-human SPECT/CT images of
[203Pb]PSV359 from an independent investigator revealed strong
tumor uptake, fast clearance through the renal system, low
accumulation in normal organs, and long tumor retention in three
patients with FAP expressing cancers. The results were presented at
the EANM meeting in October 2024.Preclinical results were presented
during the Society of Nuclear Medicine and Molecular Imaging
(SNMMI) and EANM meetings in June and October 2024, respectively.
Researchers presented a novel cyclic peptide targeting human FAP,
which was discovered by us via phage display methods. FAP is a
protein abundantly expressed in certain cancer cells as well as
cancer-associated fibroblasts in tumor lesions and involved in
promoting disease progression. The peptide was conjugated to a lead
(Pb)-specific chelator via a molecular linker to form a novel
construct, PSV359. The purpose of this study was to evaluate the in
vitro and in vivo performance of [203/212Pb]PSV359 in preclinical
xenograft models. PSV359 demonstrated superior binding affinity and
specificity against human FAP (Kd=1.8 nM, Ki=0.4 nM) and remained
stable in serum for 96 hours. Overall, strong anti-tumor clinical
activity of [212Pb]PSV359 was found in both HT1080-human FAP (FAP
on cancer cells) and U87MG (FAP in stromal tissues) xenograft
models.We are on track to file an IND in late 2024 for this new
asset. If the study may proceed, the U.S. Phase I study would
commence in 2025.
- PSV40X is a technology targeting prostate
specific membrane antigen (PSMA) which we acquired through a
license agreement with Mayo Clinic for the rights to Mayo’s PSMA
Alpha-PET DoubLET platform, with an initial focus on prostate
cancer derived tumors. This radiopharmaceutical platform provides
detailed PET imaging-based diagnosis and dosimetry using long-lived
copper-64 (64Cu) for imaging and alpha-particle targeted therapies
using 212Pb. Preclinical studies are ongoing to assess whether this
new molecular entity meets the hurdle for progressing into the
clinic with potential to achieve best-in-class profile.
- Pre-targeting is technology enabling the use
of antibodies to direct radiolabeled ligands to tumor sites.
Antibodies can bind with high specificity to a wider variety of
cancer-specific proteins preferentially expressed on the surface of
tumor cells. However, the amount of time required for an adequate
amount of antibodies to bind to the cancer-specific proteins may
not align with the properties of the desired isotope. By attaching
an additional chemical entity to an antibody that would bind to a
radioligand, the resultant modified antibodies may be administered
separately from and in advance of the radioligand as appropriate.
Preclinical optimization of this platform is underway, and initial
targeting antibodies have been identified for further
investigation.
Other Business Highlights
- On September 18, 2024, we entered
into a Master Equipment and Services Agreement (MESA) and
statements of work (SOWs) thereunder with Comecer SpA (Comecer),
pursuant to which we agreed to purchase from Comecer manufacturing
equipment for the production of our radiopharmaceutical products
including, but not limited to, isotope processing hot cells and
production suites and related equipment (collectively, the
Deliverables) and services for installation and validation of the
Deliverables at several of our production facilities in the United
States. The aggregate consideration for such equipment and services
pursuant to the MESA and SOWs is approximately €49.0 million
payable in cash, excluding certain incidental costs such as taxes,
customs and duties, local transport, insurance and rigging. We may
also elect to purchase certain additional equipment and services
pursuant to the SOWs. The MESA provides for the payment of certain
amounts in installments over the course of the production,
installation and validation of the Deliverables.
- On July 15, 2024, August 2, 2024
and October 31, 2024, we purchased a building located in the
Houston, Texas, metropolitan area for $4.7 million, a building in
the Chicago, Illinois, metropolitan area for $5.0 million, and a
building in the Los Angeles, California, metropolitan area for
$11.0 million, respectively, which we intend to use for the
manufacture of our program candidates upon completion of
modifications and installation of equipment.
- We completed our first shipment and
patient dosing of 212Pb-labeled radiopharmaceuticals from our newly
operational manufacturing facility in Somerset, New Jersey. This
second facility, equipped with three manufacturing suites that can
meet Current Good Manufacturing Practice (cGMP) requirements, joins
the Coralville, Iowa, site in supplying investigational products
for VMT-α-NET clinical studies. With expanded capacity, the
Somerset facility is well-positioned to meet growing clinical trial
and future commercial demands across major cancer centers in the
Northeastern U.S. Previously operated by Lantheus Holdings, Inc.,
this facility previously produced the FDA-approved
radiopharmaceutical Azedra for rare adrenal tumors.
- Our patent portfolio was further
strengthened by the issuance of two additional patents. The first
patent, issued in the U.S., pertains to the creation of
radiopharmaceutical compounds using lead-specific chelators. This
patent has been exclusively licensed to us by the University of
Iowa and expires in 2037. The second patent, issued in Australia,
pertains to VMT01.
Third Quarter 2024 Financial
Summary
Cash, cash equivalents, and short-term
investments as of September 30, 2024 was $267.8
million as compared to $9.2 million as of December 31, 2023.
Based on our current plans, which include advancing current
clinical programs based on readout, progressing multiple pre-IND
assets towards clinical trials, as well as developing several
regional manufacturing sites, we expect to have sufficient funding
into mid-2026.
In August 2024, we entered into a Controlled
Equity OfferingSM Sales Agreement (2024 ATM Agreement) with Cantor
Fitzgerald & Co. and RBC Capital Markets, LLC (each, an ATM
Agent, and together, the ATM Agents) pursuant to which we, from
time to time, may offer and sell shares (2024 ATM Shares) of our
Common Stock, through or to the 2024 ATM Agents having an aggregate
sales price of up to $250.0 million. Sales of the 2024 ATM Shares,
if any, under the 2024 ATM Agreement may be made in transactions
that are deemed to be “at the market offerings” as defined in Rule
415 under the Securities Act of 1933, as amended. We have no
obligation to sell any of the 2024 ATM Shares and may at any time
suspend offers under the 2024 ATM Agreement or terminate the 2024
ATM Agreement. As of September 30, 2024, we have not completed
any transactions pursuant to the 2024 ATM Agreement.
As of September 30, 2024, we had 67.5
million shares of common stock, 7.7 million warrants and options to
purchase shares of common stock, and 3.2 million pre-funded
warrants outstanding.
We previously presented our results in two
segments: Drug Operations and Brachytherapy. Due to the divestiture
of our entire brachytherapy segment to GT Medical in April 2024,
the assets and operations of the brachytherapy segment have been
classified as discontinued operations in our financial statements.
The discussion below pertains to continuing operations unless
otherwise noted.
Grant revenue for the three
months ended September 30, 2024 was $0.4 million, compared to
$0.3 million for the same period in 2023, an increase of
approximately 33%. Grant revenue for the nine months ended
September 30, 2024 was $1.2 million, compared to $1.1 million
for the same period in 2023, an increase of approximately 9%. Grant
revenue is derived from our work with the National Institutes of
Health.
Research and development
expenses were $12.0 million for the three months ended
September 30, 2024, compared to $5.6 million for the same
period in 2023, an increase of approximately 114%. Research and
development expenses for the nine months ended September 30,
2024 were $28.8 million, compared to $14.2 million for the same
period in 2023, an increase of approximately 103%. Management
believes that research and development expenses will continue to
increase as we continue to invest in the development of novel
radiopharmaceutical drugs and products and expand our manufacturing
capabilities.
General and administrative
expenses were $7.0 million for the three months ended
September 30, 2024, compared to $4.5 million for the same
period in 2023, an increase of approximately 56%. General and
administrative expenses for the nine months ended
September 30, 2024 were $18.4 million, compared to $16.1
million for the same period in 2023, an increase of approximately
14%. The increase in general and administrative expenses during the
three and nine months ended September 30, 2024, was due to
increased personnel costs as well as increased fees for
professional services, taxes and insurance.
Total operating expenses for
the three months ended September 30, 2024 were $19.0 million,
compared to $10.0 million for the same period in 2023, an increase
of approximately 90%. Total operating expenses for the nine months
ended September 30, 2024 were $47.1 million, compared to $30.4
million for the same period in 2023, an increase of approximately
55%.
Net loss from continued and
discontinued operations for the three months ended
September 30, 2024 was $15.1 million, or $0.21 loss per basic
and diluted share, compared to a net loss of $10.4 million, or
$0.37 per basic and diluted share, for the same period in 2023
after adjusting for the 1-for-10 reverse stock split effective as
of June 14, 2024 (Reverse Split). Net loss from continued and
discontinued operations for the nine months ended
September 30, 2024 was $39.1 million, or $0.62 per basic and
diluted share, compared to a net loss of $21.8 million, or $0.83
per basic and diluted share, for the same period in 2023 after
adjusting for the Reverse Split.
About Perspective Therapeutics,
Inc.Perspective Therapeutics, Inc., is a
radiopharmaceutical development company that is pioneering advanced
treatment applications for cancers throughout the body. The Company
has proprietary technology that utilizes the alpha-emitting isotope
212Pb to deliver powerful radiation specifically to cancer cells
via specialized targeting moieties. The Company is also developing
complementary imaging diagnostics that incorporate the same
targeting moieties, which provide the opportunity to personalize
treatment and optimize patient outcomes. This “theranostic”
approach enables the ability to see the specific tumor and then
treat it to potentially improve efficacy and minimize toxicity.
The Company’s melanoma (VMT01) and
neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a
imaging and therapy trials for the treatment of metastatic melanoma
and neuroendocrine tumors at several leading academic institutions.
The Company has also developed a proprietary 212Pb generator to
secure key isotopes for clinical trial and commercial
operations.
For more information, please visit the Company’s
website at https://www.perspectivetherapeutics.com/.
Safe Harbor StatementThis press
release contains forward-looking statements within the meaning of
the United States Private Securities Litigation Reform Act of 1995.
Statements in this press release that are not statements of
historical fact are forward-looking statements. Words such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “estimate,” “believe,” “predict,”
“potential,” or “continue” or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, though not all forward-looking statements contain these
identifying words. Forward-looking statements in this press release
include statements concerning, among other things, the Company’s
ability to pioneer advanced treatment applications for cancers
throughout the body; the Company’s belief that it will continue to
advance and make progress with its clinical-stage proprietary
radiopharmaceuticals; the Company’s belief that it will advance
multiple pre-IND assets into the clinic in the next 9-18 months;
the Company’s expectation that its current cash, cash equivalents
and short-term investments balance will be sufficient to fund its
current planned operations and capital investments into mid-2026;
the Company’s ability to bring innovative precision medicines to
patients based on alpha-emitting isotopes and targeting moiety
optimization; the potential for VMT01 to be administered as a
single agent or in combination with other agents and for the
Company to explore different dose levels in connection with its
VMT01 trial; the potential for PSV359 to demonstrate improved
legals of target engagement and uptake in tumors and reduced
retention in healthy tissues that may result in a desirable
therapeutic index; the Company’s plans to file an IND in late 2024
for PSV359; the ability of PSV40X to meet the hurdle for
progressing into the clinic with potential to achieve best-in-class
profile; the potential for pre-targeting technology to enhance
targeting of tumors, and the potential success of the Company in
advancing such technology; the Company’s expectation that it will
continue making progress on building out of its manufacturing
infrastructure network; the Company’s intention to use the acquired
buildings to manufacture materials for patient administration upon
completion of modifications and installation of equipment; the
Company’s belief that research and development expenses will
increase from current levels as the Company continues to invest in
the development of novel radiopharmaceutical drugs and products and
expands its manufacturing capabilities; the Company’s prediction
that complementary imaging diagnostics that incorporate certain
targeting moieties provide the opportunity to personalize treatment
and optimize patient outcomes; the Company's expectation that its
“theranostic” approach enables the ability to see specific tumors
and then treat them to potentially improve efficacy and minimize
toxicity; the Company’s ability to develop a proprietary 212Pb
generator to secure key isotopes for clinical trial and commercial
operations; the Company’s clinical development plans and the
expected timing thereof; the expected timing for availability and
release of data; expectations regarding the potential market
opportunities for the Company’s product candidates; the potential
functionality, capabilities and benefits of the Company’s product
candidates and the potential application of these product
candidates for other disease indications; the Company’s
expectations, beliefs, intentions, and strategies regarding the
future; the Company’s intentions to improve important aspects of
care in cancer treatment; and other statements that are not
historical fact.
The Company may not actually achieve the plans,
intentions, or expectations disclosed in the forward-looking
statements and you should not place undue reliance on the
forward-looking statements. These forward-looking statements
involve risks and uncertainties that could cause the Company’s
actual results to differ materially from the results described in
or implied by the forward-looking statements, including, without
limitation, the potential that regulatory authorities may not grant
or may delay approval for the Company’s product candidates;
uncertainties and delays relating to the design, enrollment,
completion, and results of clinical trials; unanticipated costs and
expenses; early clinical trials may not be indicative of the
results in later clinical trials; clinical trial results may not
support regulatory approval or further development in a specified
indication or at all; actions or advice of regulatory authorities
may affect the design, initiation, timing, continuation, and/or
progress of clinical trials or result in the need for additional
clinical trials; the Company’s ability to obtain and maintain
regulatory approval for the Company’s product candidates; delays,
interruptions, or failures in the manufacture and supply of the
Company’s product candidates; the size and growth potential of the
markets for the Company’s product candidates, and the Company’s
ability to service those markets; the Company’s cash and cash
equivalents may not be sufficient to support its operating plan for
as long as anticipated; uncertainties regarding the Company’s
expectations, projections, and estimates regarding expenses, future
revenue, capital requirements, and the availability of and the need
for additional financing; the Company’s ability to obtain
additional funding to support its clinical development programs;
the availability or potential availability of alternative products
or treatments for conditions targeted by the Company that could
affect the availability or commercial potential of its product
candidates; the ability of the Company to manage growth; the
Company’s ability to maintain its key employees; sufficient
training and use of the Company’s products and product candidates;
the market acceptance and recognition of the Company’s programs and
program candidates; the Company’s ability to maintain and enforce
its intellectual property rights; the Company’s ability to maintain
its therapeutic isotope supply agreement with the Department of
Energy; the Company’s ability to continue to comply with the
procedures and regulatory requirements mandated by the FDA for
additional trials, Phase 1 and 2 approvals, Fast Track approvals,
and 510(k) approval and reimbursement codes; and any changes in
applicable laws and regulations. Other factors that may cause the
Company’s actual results to differ materially from those expressed
or implied in the forward-looking statements in this press release
are described under the heading “Risk Factors” in the Company’s
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (the SEC),
in the Company’s other filings with the SEC, and in the Company’s
future reports to be filed with the SEC and available at
www.sec.gov. Forward-looking statements contained in this news
release are made as of this date. Unless required to do so by law,
the Company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Media and Investor Relations
Contacts:
Perspective Therapeutics IR
Annie Cheng ir@perspectivetherapeutics.com
Russo Partners, LLCNic
Johnsonperspectivetx@russopr.com
|
|
|
|
Perspective Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets(In
thousands) |
|
|
|
|
|
September 30, |
|
December 31, |
|
2024 |
|
2023 |
|
(unaudited) |
|
|
Cash, cash equivalents and short-term investments |
$ |
267,847 |
|
$ |
9,238 |
Total assets |
|
391,153 |
|
|
97,891 |
Total liabilities |
|
62,682 |
|
|
22,712 |
Total stockholders' equity |
|
328,471 |
|
|
75,179 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Perspective Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and
Comprehensive Loss(In thousands, except per share
amounts)(Unaudited) |
|
|
|
|
|
|
|
Three Months EndedSeptember 30, |
|
|
Nine Months EndedSeptember 30, |
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant revenue |
$ |
369 |
|
|
$ |
276 |
|
|
$ |
1,220 |
|
|
$ |
1,097 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
12,028 |
|
|
|
5,552 |
|
|
|
28,755 |
|
|
|
14,231 |
|
General and administrative |
|
6,975 |
|
|
|
4,474 |
|
|
|
18,367 |
|
|
|
16,124 |
|
Change in estimate of asset retirement obligation |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(15 |
) |
Loss on disposal of property and equipment |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
22 |
|
Total operating expenses |
|
19,003 |
|
|
|
10,026 |
|
|
|
47,122 |
|
|
|
30,362 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
(18,634 |
) |
|
|
(9,750 |
) |
|
|
(45,902 |
) |
|
|
(29,265 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Total non-operating income
(expense), net |
|
3,512 |
|
|
|
178 |
|
|
|
7,741 |
|
|
|
802 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss from continuing operations |
|
(15,122 |
) |
|
|
(9,572 |
) |
|
|
(38,161 |
) |
|
|
(28,463 |
) |
Net loss from discontinued operations |
|
- |
|
|
|
(784 |
) |
|
|
(890 |
) |
|
|
(3,870 |
) |
Loss recognized on classification as held for sale |
|
- |
|
|
|
- |
|
|
|
(59 |
) |
|
|
- |
|
Net loss before income taxes |
|
(15,122 |
) |
|
|
(10,356 |
) |
|
|
(39,110 |
) |
|
|
(32,333 |
) |
Deferred income tax benefit |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
10,500 |
|
Net loss |
$ |
(15,122 |
) |
|
$ |
(10,356 |
) |
|
$ |
(39,110 |
) |
|
$ |
(21,833 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per
share: |
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations1 |
$ |
(0.21 |
) |
|
$ |
(0.34 |
) |
|
$ |
(0.61 |
) |
|
$ |
(0.68 |
) |
Loss from discontinued operations1 |
|
- |
|
|
|
(0.03 |
) |
|
|
(0.01 |
) |
|
|
(0.15 |
) |
Basic and diluted loss per share1 |
$ |
(0.21 |
) |
|
$ |
(0.37 |
) |
|
$ |
(0.62 |
) |
|
$ |
(0.83 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in
computing net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted1 |
|
70,629 |
|
|
|
28,055 |
|
|
|
62,293 |
|
|
|
26,323 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. Amounts for prior
periods presented have been retroactively adjusted to reflect the
Reverse Split. |
Bristol Myers Squibb (NYSE:BMY)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Bristol Myers Squibb (NYSE:BMY)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024